C-di-GMP enhances protective innate immunity in a murine model of pertussis

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Elahi, Shokrollah ^a   Van Kessel, Jill ^b   Kiros, Tedele G ^c   Strom, Stacy ^b   Hayakawa, Yoshihiro ^d   Hyodo, Mamoru ^d   Babiuk, Lorne A ^a   Gerdts, Volker ^b,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d AICHI INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC BIS(3'-5')DIGUANYLIC ACID; CYTOKINE; GAMMA INTERFERON; IMMUNOSTIMULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIS(3',5')-CYCLIC DIGUANYLIC ACID; CYCLIC GMP;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL LOAD; BORDETELLA PERTUSSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG PURITY; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INNATE IMMUNITY; LUNG HOMOGENATE; MOUSE; NONHUMAN; PERTUSSIS; PHENOTYPE; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANIMAL; DENDRITIC CELL; DISEASE MODEL; DRUG EFFECTS; IMMUNE SYSTEM; IMMUNOLOGY; MACROPHAGE; NATURAL KILLER CELL; NEUTROPHIL; RESPIRATORY SYSTEM; WHOOPING COUGH;

MURINAE;

ANIMALS; BORDETELLA PERTUSSIS; CYCLIC GMP; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNE SYSTEM; IMMUNITY, INNATE; KILLER CELLS, NATURAL; MACROPHAGES; MICE; NEUTROPHILS; RESPIRATORY SYSTEM; WHOOPING COUGH;

EID: 84908102137     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109778     Document Type: Article

References (63)

1. Rodgers L, Martin SW, Cohn A, Budd J, Marcon M, et al. (2013) Epidemiologic and Laboratory Features of a Large Outbreak of Pertussis-Like Illnesses Associated With Cocirculating Bordetella holmesii and Bordetella pertussis-Ohio, 2010-2011. Clinical Infectious Diseases 56: 322-331.
2. Barbic J, Leef MF, Burns DL, Shahin RD (1997) Role of gamma interferon in natural clearance of Bordetella pertussis infection. Infect Immun 65: 4904-4908.
3. Kenyon C, Miller C, Ehresmann K (2004) Fata case of umsuspected pertussis diagnosed from a blood culture. MMWR 53: 131-132.
4. Cherry JD (2012) Epidemic pertussis in 2012-the resurgence of a vaccinepreventable disease. N Engl J Med 367: 785-787.
5. Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, et al. (2011) Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 11: 557-570.
6. Halperin SA, Issekutz TB, Kasina A (1991) Modulation of Bordetella pertussis infection with monoclonal antibodies to pertussis toxin. J Infect Dis 163: 355-361.
7. Mountzouros KT, Kimura A, Cowell JL (1992) A bactericidal monoclonal antibody specific for the lipooligosaccharide of Bordetella pertussis reduces colonization of the respiratory tract of mice after aerosol infection with B. pertussis. Infect Immun 60: 5316-5318.
8. Redhead K, Watkins J, Barnard A, Mills KH (1993) Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 61: 3190-3198.
9. Shahin RD, Brennan MJ, Li ZM, Meade BD, Manclark CR (1990) Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med 171: 63-73.
10. Shahin RD, Hamel J, Leef MF, Brodeur BR (1994) Analysis of protective and nonprotective monoclonal antibodies specific for Bordetella pertussis lipooligosaccharide. Infect Immun 62: 722-725.
11. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, et al. (1996) A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 334: 341-348.
12. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J (1996) A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334: 349-355.
13. Mills KH, Barnard A, Watkins J, Redhead K (1993) Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 61: 399-410.
14. Mahon BP, Brady MT, Mills KH (2000) Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for longterm immunity in children. J Infect Dis 181: 2087-2091.
15. Mahon BP, Sheahan BJ, Griffin F, Murphy G, Mills KH (1997) Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes. J Exp Med 186: 1843-1851.
16. Mahon BP, Ryan MS, Griffin F, Mills KH (1996) Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect Immun 64: 5295-5301.
17. Mobberley-Schuman PS, Weiss AA (2005) Influence of CR3 (CD11b/CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils. Infect Immun 73: 7317-7323.
18. Wolfe DN, Mann PB, Buboltz AM, Harvill ET (2007) Delayed Role of Tumor Necrosis Factor- alpha in Overcoming the Effects of Pertussis Toxin. J Infect Dis 196: 1228-1236.
19. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH (2006) TLR4 mediates vaccineinduced protective cellular immunity to Bordetella pertussis: role of IL-17- producing T cells. J Immunol 177: 7980-7989.
20. Byrne P, McGuirk P, Todryk S, Mills KH (2004) Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells. Eur J Immunol 34: 2579-2588.
21. Toews GB, Gross GN, Pierce AK (1979) The relationship of inoculum size to lung bacterial clearance and phagocytic cell response in mice. Am Rev Respir Dis 120: 559-566.
22. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
23. Ferlazzo G, Morandi B, D'Agostino A, Meazza R, Melioli G, et al. (2003) The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol 33: 306-313.
24. Hellwig SM, Rodriguez ME, Berbers GA, van de Winkel JG, Mooi FR (2003) Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis 188: 738-742.
25. Kradin RL, Sakamoto H, Preffer FI, Dombkowski D, Springer KM, et al. (2000) Accumulation of macrophages with dendritic cell characteristics in the pulmonary response to Listeria. Am J Respir Crit Care Med 161: 535-542.
26. Liu CH, Fan YT, Dias A, Esper L, Corn RA, et al. (2006) Cutting edge: dendritic cells are essential for in vivo IL-12 production and development of resistance against Toxoplasma gondii infection in mice. J Immunol 177: 31-35.
27. Ross P, Weinhouse H, Aloni Y, Michaeli D, Weinberger-Ohana P, et al. (1987) Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid. Nature 325: 279-281.
28. Ross P, Mayer R, Weinhouse H, Amikam D, Huggirat Y, et al. (1990) The cyclic diguanylic acid regulatory system of cellulose synthesis in Acetobacter xylinum. Chemical synthesis and biological activity of cyclic nucleotide dimer, trimer, and phosphothioate derivatives. J Biol Chem 265: 18933-18943.
29. Valla S, Coucheron DH, Fjaervik E, Kjosbakken J, Weinhouse H, et al. (1989) Cloning of a gene involved in cellulose biosynthesis in Acetobacter xylinum: complementation of cellulose-negative mutants by the UDPG pyrophosphorylase structural gene. Mol Gen Genet 217: 26-30.
30. Jenal U (2004) Cyclic di-guanosine-monophosphate comes of age: a novel secondary messenger involved in modulating cell surface structures in bacteria? Curr Opin Microbiol 7: 185-191.
31. Jenal U, Malone J (2006) Mechanisms of cyclic-di-GMP signaling in bacteria. Annu Rev Genet 40: 385-407.
32. Karaolis DK, Newstead MW, Zeng X, Hyodo M, Hayakawa Y, et al. (2007) Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia. Infect Immun 75: 4942-4950.
33. Karaolis DK, Rashid MH, Chythanya R, Luo W, Hyodo M, et al. (2005) c-di- GMP (3′-5′-cyclic diguanylic acid) inhibits Staphylococcus aureus cell-cell interactions and biofilm formation. Antimicrob Agents Chemother 49: 1029-1038.
34. Hecht GB, Newton A (1995) Identification of a novel response regulator required for the swarmer-to-stalked-cell transition in Caulobacter crescentus. J Bacteriol 177: 6223-6229.
35. Romling U, Amikam D (2006) Cyclic di-GMP as a second messenger. Curr Opin Microbiol 9: 218-228.
36. Romling U, Gomelsky M, Galperin MY (2005) C-di-GMP: the dawning of a novel bacterial signalling system. Mol Microbiol 57: 629-639.
37. Ross P, Mayer R, Benziman M (1991) Cellulose biosynthesis and function in bacteria. Microbiol Rev 55: 35-58.
38. Karaolis DK, Means TK, Yang D, Takahashi M, Yoshimura T, et al. (2007) Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol 178: 2171-2181.
39. Brouillette E, Hyodo M, Hayakawa Y, Karaolis DK, Malouin F (2005) 3′,5′-cyclic diguanylic acid reduces the virulence of biofilm-forming Staphylococcus aureus strains in a mouse model of mastitis infection. Antimicrob Agents Chemother 49: 3109-3113.
40. Yan HB, KuoLee R, Tram K, Qiu HY, Zhang JB, et al. (2009) 3′,5′-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection. Biochemical and Biophysical Research Communications 387: 581-584.
41. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, et al. (2011) STING is a direct innate immune sensor of cyclic di-GMP. Nature 478: 515-518.
42. Kawai R, Nagata R, Hirata A, Hayakawa Y (2003) A new synthetic approach to cyclic bis(3′-.5′)diguanylic acid. Nucleic Acids Res Suppl: 103-104.
43. Halperin SA, Heifetz SA, Kasina A (1988) Experimental respiratory infection with Bordetella pertussis in mice: comparison of two methods. Clin Invest Med 11: 297-303.
44. Elahi S, Pang G, Ashman RB, Clancy R (2001) Nitric oxide-enhanced resistance to oral candidiasis. Immunology 104: 447-454.
45. Elahi S, Buchanan R, Attah-Poku S, Townsend H, Babiuk LA, et al. (2005) The host defense peptide beta-defensin 1 confers protection against Bordetella pertussis in newborn piglets. Infect Immun Submitted.
46. Tsai WC, Strieter RM, Zisman DA, Wilkowski JM, Bucknell KA, et al. (1997) Nitric oxide is required for effective innate immunity against Klebsiella pneumoniae. Infect Immun 65: 1870-1875.
47. Rollins-Smith LA, Doersam JK, Longcore JE, Taylor SK, Shamblin JC, et al. (2002) Antimicrobial peptide defenses against pathogens associated with global amphibian declines. Dev Comp Immunol 26: 63-72.
48. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415: 389-395.
49. Brady MT, Mahon BP, Mills KH (1998) Pertussis infection and vaccination induces Th1 cells. Immunol Today 19: 534.
50. Greenberger MJ, Kunkel SL, Strieter RM, Lukacs NW, Bramson J, et al. (1996) IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 157: 3006-3012.
51. Mills KH (2001) Immunity to Bordetella pertussis. Microbes Infect 3: 655-677.
52. Ye J, Ortaldo JR, Conlon K, Winkler-Pickett R, Young HA (1995) Cellular and molecular mechanisms of IFN-gamma production induced by IL-2 and IL-12 in a human NK cell line. J Leukoc Biol 58: 225-233.
53. Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, et al. (2013) Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog 9: e1003264.
54. Torre D, Pugliese A, Speranza F, Fiori GP, Perversi L, et al. (1993) Interferongamma levels in serum and bronchoalveolar lavage fluid of mice infected with Bordetella pertussis. J Infect Dis 167: 762-765.
55. Torre D, Ferrario G, Bonetta G, Perversi L, Speranza F (1996) In vitro and in vivo induction of nitric oxide by murine macrophages stimulated with Bordetella pertussis. FEMS Immunol Med Microbiol 13: 95-99.
56. Xing DK, Canthaboo C, Corbel MJ (2000) Effect of pertussis toxin on the induction of nitric oxide synthesis in murine macrophages and on protection in vivo. Vaccine 18: 2110-2119.
57. Mahon BP, Mills KH (1999) Interferon-gamma mediated immune effector mechanisms against Bordetella pertussis. Immunol Lett 68: 213-217.
58. Sakurai S, Kamachi K, Konda T, Miyajima N, Kohase M, et al. (1996) Nitric oxide induction by pertussis toxin in mouse spleen cells via gamma interferon. Infect Immun 64: 1309-1313.
59. Canthaboo C, Xing D, Corbel M (1999) Development of a nitric oxide induction assay as a potential replacement for the intracerebral mouse protection test for potency assay of pertussis whole cell vaccines. Dev Biol Stand 101: 95-103.
60. Canthaboo C, Xing D, Wei XQ, Corbel MJ (2002) Investigation of role of nitric oxide in protection from Bordetella pertussis respiratory challenge. Infect Immun 70: 679-684.
61. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R (2012) Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 367: 1012-1019.
62. Ausiello CM, Urbani F, La Sala A, Lande R, Piscitelli A, et al. (1997) Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Dev Biol Stand 89: 315-320.
63. Ryan M, Murphy G, Ryan E, Nilsson L, Shackley F, et al. (1998) Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93: 1-10.